Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Toename behandelopties voor subgroep met HER2-positief coloncarcinoom
sep 2023 | Maag-darm-leveroncologie